Evidence map›Paper›PMID 40762798›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Histopathologic outcomes of hepatocellular carcinoma treated with transarterial radioembolization with yttrium-90 resin microspheres.

Ammar Sarwar, Imad Nasser, Jeffrey L Weinstein, Mahmoud Odeh, Hafsa Babar, Diana Dinh, Michael Curry, Andrea Bullock, Devin Eckhoff, Martin Dib and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ammar SarwarDivision of Interventional Radiology, Department of Radiology, Beth Israel Deaconess Medical Center, 1 Deaconess Road Rosenberg 3, Boston, MA, 02215, USA. asarwar@bidmc.harvard.edu.ORCID 0000-0003-2254-9881
Imad NasserDepartment of Pathology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Jeffrey L WeinsteinDivision of Interventional Radiology, Department of Radiology, Beth Israel Deaconess Medical Center, 1 Deaconess Road Rosenberg 3, Boston, MA, 02215, USA.
Mahmoud OdehDivision of Interventional Radiology, Department of Radiology, Beth Israel Deaconess Medical Center, 1 Deaconess Road Rosenberg 3, Boston, MA, 02215, USA.
Hafsa BabarDepartment of Radiology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Diana DinhDivision of Interventional Radiology, Department of Radiology, Beth Israel Deaconess Medical Center, 1 Deaconess Road Rosenberg 3, Boston, MA, 02215, USA.
Michael CurryDivision of Hepatology and Gastroenterology, Department of Internal Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Andrea BullockDivision of Hematology and Medical Oncology, Department of Internal Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Devin EckhoffDivision of Transplantation, Department of Surgery, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Martin DibDivision of Transplantation, Department of Surgery, Beth Israel Deaconess Medical Center, Boston, MA, USA.
John A ParkerDivision of Nuclear Medicine, Department of Radiology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Muneeb AhmedDivision of Interventional Radiology, Department of Radiology, Beth Israel Deaconess Medical Center, 1 Deaconess Road Rosenberg 3, Boston, MA, 02215, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate the pathologic outcomes of 90Y-TARE of HCC with resin microspheres prescribed using the single-compartment model and to correlate posttreatment dose with outcomes.

methodsThis retrospective single-center study included adult patients with HCC who underwent 90Y-TARE with resin microspheres before liver transplantation or surgery. Histopathologic evaluation of liver tissue was performed. Complete pathologic necrosis (CPN) was defined as 100% tumor necrosis, extensive necrosis as 50-99%, and partial necrosis as < 50%. Posttreatment voxel-based dosimetry was conducted. Additional subgroup analysis was done to compare tumors with complete and incomplete necrosis.

resultsAmong 28 patients (median age, 64 years [IQR, 57-69 years]); 86% males,75% BCLC 0-A) with 37 HCC tumors, complete, extensive and partial pathologic necrosis were achieved in 27/37(73%), 8/37(22%) and 2/37(5%) tumors, respectively. Tumors with CPN were significantly smaller than those without CPN (2.2 vs. 3.4 cm, P = 0.03), with longer interval between the 90Y-TARE and liver surgery (274 vs. 143 days, P = 0.048). All tumors with a mean tumor absorbed dose ≥ 433 Gy had CPN. Conversely, all tumors in which 4% or more of the tumor volume received a dose less than 100 Gy had incomplete necrosis. ROC analysis identified D95 ≥ 133 Gy (AUC 0.96 [95%CI: 0.9-1]) and V0-100 (%) < 5% (AUC 0.9 [95%CI: 0.75-0.97]) as predictors of CPN with 100% and 78% specificity, respectively.

conclusionAmong HCC patients who underwent 90Y-TARE with resin microspheres, 73% achieved complete pathologic necrosis. All tumors with a mean tumor absorbed dose ≥ 433 Gy achieved CPN. CLINICAL TRIAL NUMBER: not applicable.

Indexed as

Carcinoma, HepatocellularEmbolization, TherapeuticLiver NeoplasmsMicrospheresYttrium RadioisotopesAgedFemaleHumansMaleMiddle AgedNecrosisRetrospective StudiesTreatment OutcomeYttrium-90Yttrium RadioisotopesComplete pathologic necrosisHepatocellular carcinomaHistopathologyRadioembolizationResinYttrium-90

Identifiers

PMID40762798

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.